

Executive Summary

PBM	Contract Type	1-Year Comparative Value	1-Year Comparative Value %	3-Year Comparative Value Total	3-Year Comparative Value Total %	1-Year Comparative Value Without Rebates	1-Year Comparative Value Without Rebates %	Pharmacy Disruption	Formulary Disruption	Negative Formulary Tier Change	Downtier (Positive) Formulary Change
SmithRx	Pass-through	\$2,260,693	24.9%	\$8,675,915	27.9%	\$786,761	6.7%	0.0%	1.5%	0.1%	1.1%
Rightway BAFO	Pass-through	\$1,729,519	19.0%	\$5,877,221	18.9%	\$670,022	5.7%	0.6%	1.9%	2.5%	1.8%
Rightway	Pass-through	\$1,500,011	16.5%	\$5,153,285	16.6%	\$610,054	5.2%	0.6%	1.9%	2.5%	1.8%
RxB ESI BAFO	Pass-through	\$499,845	5.5%	\$1,609,699	5.2%	-\$38,633	-0.3%	Incumbent			
RxB ESI	Pass-through	\$149,648	1.6%	\$537,654	1.7%	-\$119,080	-1.0%				

*Year 3 Comparative Value: Lockton-Excelsior will complete a Market Check following the initial (18) months of the 3-year agreement to renegotiate pricing

PBM order is based on initial bid \$ comparative value – highest to lowest

- Financials do not reflect any member cost share components.
- Pharmacy Disruption: percentage of members impacted.
- Formulary Exclusions: percentage of members with drug excluded from coverage.
- Formulary Tier Change: percentage of members impacted by increased cost share.